EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications

Sudhir Agrawal iD

Current Protocols · 2026

DOI: 10.1002/cpz1.70319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Protocols, 2026. Verfasst von Sudhir Agrawal. Beteiligte Einrichtung: ARNAY Sciences, Shrewsbury, MA. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oligonucleotide‐based therapeutics are now widely used in clinical settings. From the late 1980s to the mid‐1990s, efforts to improve therapeutic efficacy focused on imparting drug‐like properties to oligonucleotides, emphasizing nuclease stability and target sequence affinity. These efforts resulted in the standard gapmer design for RNase H–mediated antisense and the prevalent use of chemical modification such as phosphorothioate and 2′‐substituted oligoribonucleotides in oligonucleotide therapeutics. Progress made in the antisense field also enabled the development of splice‐modulating oligonucleotide therapeutics and later siRNA therapies. All three modes of action are now widely employed in >25 approved drugs. Since then, we have learned that oligonucleotides and their chemical modifications can interact with pattern recognition receptors as well as various other proteins. This can have both positive and negative effects, such as aiding in oligonucleotide delivery or activating the intracellular innate immune system. My current work aims to optimize the drug‐like properties of oligonucleotides by combining the early chemical advances with the more recent insights into off‐target protein binding. The present article describes how this resulted in several different cyclic structured oligonucleotide designs, in which 3′ and 5′ ends are transiently held together via Watson‐Crick base pairing. The transient nature of these cyclic structures protects the functional parts of the structure against nucleases during delivery and cell entry while allowing effective release of the oligonucleotide drug into the intracellular environment. These cyclic designs demonstrate significant improvements in potency and specificity over gapmer antisense and are broadly applicable to potentially all types of RNA therapeutics, irrespective of their mechanism of action. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesHumansOligonucleotides, AntisenseNucleic Acid Conformation

Stichwörter der Autor:innen

circular structurecyclic structuredeliverynuclease resistancenucleic acidsoligonucleotide therapeutics

Substanzen

OligonucleotidesOligonucleotides, Antisense

Autor:innen und Institutionen

  • ARNAY Sciences, Shrewsbury, MA.

ORCID-Profile: Sudhir Agrawal

Zitieren

APA

Agrawal, S. (2026). Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications. Current Protocols. https://doi.org/10.1002/cpz1.70319

Vancouver

Agrawal S. Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications. Current Protocols. 2026. doi:10.1002/cpz1.70319

BibTeX
@article{Agrawal2026,
  author = {Agrawal, Sudhir},
  title = {Transient Cyclic Structured Oligonucleotide Designs for Therapeutic Applications},
  journal = {Current Protocols},
  year = {2026},
  doi = {10.1002/cpz1.70319}
}
Kostenlos starten →